抗菌药物联合对大鼠模型中产KPC-2肺炎克雷伯菌的活性及时间杀菌试验
Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.
作者信息
Toledo Paula Virginia Michelon, Aranha Junior Ayrton Alves, Arend Lavinia Nery, Ribeiro Vanessa, Zavascki Alexandre Prehn, Tuon Felipe Francisco
机构信息
Internal Medicine Postgraduate Training, Universidade Federal do Paraná, Curitiba, Brazil Medicine Department, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil
Medicine Department, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil Anatomy Department, Universidade Federal do Paraná, Curitiba, Brazil.
出版信息
Antimicrob Agents Chemother. 2015 Jul;59(7):4301-4. doi: 10.1128/AAC.00323-15. Epub 2015 Apr 20.
Abstract
This study evaluated the efficacy of tigecycline (TIG), polymyxin B (PMB), and meropenem (MER) in 80 rats challenged with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae infection. A time-kill assay was performed with the same strain. Triple therapy and PMB+TIG were synergistic, promoted 100% survival, and produced negative peritoneal cultures, while MER+TIG showed lower survival and higher culture positivity than other regimens (P = 0.018) and was antagonistic. In vivo and in vitro studies showed that combined regimens, except MER+TIG, were more effective than monotherapies for this KPC-producing strain.
摘要
本研究评估了替加环素（TIG）、多粘菌素B（PMB）和美罗培南（MER）对80只受到产肺炎克雷伯菌碳青霉烯酶（KPC）的肺炎克雷伯菌感染的大鼠的疗效。对同一菌株进行了时间杀菌试验。三联疗法和PMB+TIG具有协同作用，可使100%的大鼠存活，并使腹腔培养结果为阴性，而MER+TIG的存活率较低，培养阳性率高于其他治疗方案（P = 0.018），且具有拮抗作用。体内和体外研究表明，除MER+TIG外，联合治疗方案对该产KPC菌株比单一疗法更有效。
相似文献
1
Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.
Antimicrob Agents Chemother. 2015 Jul;59(7):4301-4. doi: 10.1128/AAC.00323-15. Epub 2015 Apr 20.
2
Study of Synergistic Bactericidal Activity of Dual β-Lactam Antibiotics Against KPC-2-Producing .
Microb Drug Resist. 2020 Mar;26(3):204-210. doi: 10.1089/mdr.2019.0126. Epub 2019 Sep 25.
3
Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.
Int J Antimicrob Agents. 2018 Jul;52(1):114-118. doi: 10.1016/j.ijantimicag.2018.02.010. Epub 2018 Feb 24.
4
Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
J Infect Dis. 2013 Mar 1;207(5):786-93. doi: 10.1093/infdis/jis766. Epub 2012 Dec 13.
5
Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Int J Antimicrob Agents. 2011 Mar;37(3):244-7. doi: 10.1016/j.ijantimicag.2010.10.031. Epub 2011 Jan 13.
6
In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
J Antimicrob Chemother. 2014 Jul;69(7):1856-65. doi: 10.1093/jac/dku065. Epub 2014 Mar 19.
7
Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.02121-16. Print 2017 Feb.
8
Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2006 Jun;50(6):2258-60. doi: 10.1128/AAC.01513-05.
9
Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
Int J Antimicrob Agents. 2019 Feb;53(2):152-157. doi: 10.1016/j.ijantimicag.2018.10.010. Epub 2018 Oct 26.
10
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Antimicrob Agents Chemother. 2012 Apr;56(4):2108-13. doi: 10.1128/AAC.06268-11. Epub 2012 Jan 17.
引用本文的文献
1
Combined therapeutic option for NDM-producing Serratia Marcescens - an in vitro study from clinical samples.
Braz J Infect Dis. 2025 Jan-Feb;29(1):104481. doi: 10.1016/j.bjid.2024.104481. Epub 2024 Nov 26.
2
In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing or .
Infect Drug Resist. 2023 May 23;16:3171-3182. doi: 10.2147/IDR.S408228. eCollection 2023.
3
Luteolin 4'-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo.
Molecules. 2023 Mar 13;28(6):2609. doi: 10.3390/molecules28062609.
4
Bioassay-Guided Isolation of Antimicrobial Components and LC/QToF Profile of : Potential for the Treatment of Antimicrobial Resistance.
ACS Omega. 2023 Feb 8;8(7):6476-6491. doi: 10.1021/acsomega.2c06803. eCollection 2023 Feb 21.
5
research of combination therapy for multidrug-resistant Klebsiella pneumoniae bloodstream infections.
J Int Med Res. 2022 Jun;50(6):3000605221106705. doi: 10.1177/03000605221106705.
6
Effects of Zinc Oxide Nanoparticles Synthesized Using on Carbapenem-Resistant and .
Front Cell Infect Microbiol. 2021 Nov 16;11:748739. doi: 10.3389/fcimb.2021.748739. eCollection 2021.
7
In vitro and in vivo antibacterial activity assays of carvacrol: A candidate for development of innovative treatments against KPC-producing Klebsiella pneumoniae.
PLoS One. 2021 Feb 22;16(2):e0246003. doi: 10.1371/journal.pone.0246003. eCollection 2021.
8
Antagonistic effect between tigecycline and meropenem: from bed to bench to bed.
Infection. 2020 Feb;48(1):141-142. doi: 10.1007/s15010-019-01353-y. Epub 2019 Sep 6.
9
When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.
Clin Lab Med. 2019 Sep;39(3):345-358. doi: 10.1016/j.cll.2019.04.002. Epub 2019 Jun 12.
10
The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.
Front Public Health. 2019 Jun 11;7:151. doi: 10.3389/fpubh.2019.00151. eCollection 2019.
本文引用的文献
1
Experimental model for treatment of extended spectrum betalactamase producing-Klebsiella pneumoniae.
Arq Bras Cir Dig. 2014 Jul-Sep;27(3):168-71. doi: 10.1590/s0102-67202014000300002.
2
Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae non-lethal sepsis.
Braz J Infect Dis. 2014 Sep-Oct;18(5):574-5. doi: 10.1016/j.bjid.2014.05.003. Epub 2014 Jun 5.
3
Combination therapy for carbapenem-resistant Gram-negative bacteria.
J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168. Epub 2014 May 28.
4
Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.
Antimicrob Agents Chemother. 2014;58(4):2322-8. doi: 10.1128/AAC.02166-13. Epub 2014 Feb 10.
5
Contribution of phenotypic heterogeneity to adaptive antibiotic resistance.
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):355-60. doi: 10.1073/pnas.1316084111. Epub 2013 Dec 18.
6
In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2014;58(2):874-9. doi: 10.1128/AAC.01624-13. Epub 2013 Nov 25.
7
Combination therapy for carbapenem-resistant Gram-negative bacteria.
Expert Rev Anti Infect Ther. 2013 Dec;11(12):1333-53. doi: 10.1586/14787210.2013.845523. Epub 2013 Nov 6.
8
Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.
Antimicrob Agents Chemother. 2013 Dec;57(12):6028-33. doi: 10.1128/AAC.00891-13. Epub 2013 Sep 23.
9
Risk factors for KPC-producing Klebsiella pneumoniae bacteremia.
Braz J Infect Dis. 2012 Sep-Oct;16(5):416-9. doi: 10.1016/j.bjid.2012.08.006. Epub 2012 Sep 12.
10
Pharmacokinetics and renal disposition of polymyxin B in an animal model.
Antimicrob Agents Chemother. 2012 Nov;56(11):5724-7. doi: 10.1128/AAC.01333-12. Epub 2012 Aug 20.
Zotero 插件